| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Previous Article | Next Article ![]()
Molecular and Cellular Biology, December 2007, p. 8152-8163, Vol. 27, No. 23
0270-7306/07/$08.00+0 doi:10.1128/MCB.00227-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
,
Laboratory of Cell Signaling, Graduate School of Pharmaceutical Sciences, The University of Tokyo, CREST, Japan Science and Technology Corporation and Strategic Approach to Drug Discovery and Development in Pharmaceutical Sciences, Center of Excellence (COE) program, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan,1 Department of Molecular Pathology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan2
Received 9 February 2007/ Returned for modification 18 April 2007/ Accepted 1 August 2007
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
) (14), lipopolysaccharide (11), endoplasmic reticulum (ER) stress (14), and calcium influx (19). Of the various stimuli tested, oxidative stress is one of the most potent activators of ASK1, and analyses of ASK1-deficient mice have revealed that ASK1 is required for the apoptosis induced by oxidative stress, ER stress, and TNF-
(17, 20). Studies have recently demonstrated that reactive oxygen species (ROS) play a critical role in lipopolysaccharide, ß-amyloid-, and angiotensin II-induced activations of ASK1, which appear to be involved in inflammation, neurodegenerative disorders, and cardiac hypertrophy, respectively (4, 7).
We previously identified thioredoxin (Trx) as a negative regulator of the ASK1-JNK/p38 pathway through yeast two-hybrid screening for ASK1-binding proteins (2, 17). Trx, a reduction/oxidation (redox) regulatory protein, inhibits the kinase activity of ASK1 by directly binding to the N-terminal noncatalytic region of ASK1 (amino acids 1 to 655) (10, 17). Upon treatment of cells with ROS such as hydrogen peroxide (H2O2), the oxidized form of Trx (Trx-S2), which is induced by ROS through a disulfide bridge between Cys32 and Cys35 in the active center, is dissociated from ASK1, resulting in activation of ASK1 (17). In accordance with these findings, an ASK1 mutant lacking the N-terminal region (ASK1
N) has been found to behave as a constitutively active form and to induce various cellular activities, such as apoptosis and cell differentiation (5, 17, 18). A recent study showed that Cys250 in the N-terminal region of ASK1 is required for inhibition of ASK1 activity by Trx (22). The N-terminal region of ASK1 is thus important for Trx-mediated redox regulation of ASK1 kinase activity.
ASK1 forms a silent homo-oligomer in nonstressed cells by direct interaction through the C-terminal coiled-coil (CCC) domain (21). We recently showed that endogenous ASK1 constitutively forms a high-molecular-mass complex including Trx (approximately 1,500 to 2,000 kDa), which we designated the ASK1 signalosome (16). This signalosome is present as a homo-oligomerized but still inactive form, indicating that homo-oligomerization of ASK1 through the CCC domain is required but not sufficient for ASK1 activation. Following dissociation of Trx upon ROS stimulation, the ASK1 signalosome forms an active higher-molecular-mass complex, in part by the recruitment of TNF receptor-associated factor 2 (TRAF2) and TRAF6 (16). Importantly, upon H2O2 treatment, even ASK1
CCC, a deletion mutant of the CCC oligomerization domain, can still form homo-oligomers and undergo weak activation (21). ASK1 thus appears, upon ROS stimulation, to create a new but unidentified interface within a preexisting oligomer, which is important for trans-autophosphorylation of ASK1 and formation of an active ASK1 signalosome. However, the precise mechanisms by which ASK1 is activated after its release from Trx remain to be determined.
In this study, we found that amino acids 46 to 277 of the ASK1 N-terminal region are necessary and sufficient for the association with Trx. We also found that both TRAF2 and TRAF6 preferentially associate with amino acids 384 to 655 of ASK1. ASK1 possesses not only a CCC domain but also an N-terminal coiled-coil (NCC) domain. The NCC domain, between the Trx-binding domain and the TRAF-binding domain, was required for N-terminal homophilic interaction, which promotes ROS-dependent activation of ASK1. Trx interfered with this homophilic interaction of ASK1, which was, however, enhanced by overexpression of TRAF2 or TRAF6 or by treatment with H2O2. Furthermore, knockdown of TRAF2 and TRAF6 resulted in reduced homophilic interaction of ASK1 through the N-terminal region. These findings indicate that Trx inhibits ASK1 activity by disrupting N-terminal homophilic interaction, whereas TRAF2 and TRAF6 promote this homophilic interaction and, thus, activation of ASK1.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Antibodies. Monoclonal antibodies to hemagglutinin (HA) (clones 3F10 and 12CA5) were purchased from Roche Molecular Biochemicals. A monoclonal antibody to Trx was purchased from Redox Bioscience Inc. Polyclonal antibodies to Trx and TRAF2 were purchased from Santa Cruz Biotechnology, Inc. Phospho-JNK (Thr-183/Tyr-185) antibody was purchased from Cell Signaling Technology. Anti-JNK and anti-ASK1 antibodies were purchased from Santa Cruz Biotechnology, Inc. An affinity-purified rabbit polyclonal antibody raised against phospho-ASK1 was described previously (21). An anti-Flag monoclonal antibody (M2) and anti-Flag M2-agarose affinity gel were purchased from Sigma. A polyclonal antibody to TRAF6 was purchased from MBL.
Plasmids.
pcDNA3-HA-ASK1WT, pcDNA3-HA-ASK1
N, pcDNA3-HA-ASK1
C, pcDNA3-HA-ASK1-NT, pcDNA3-HA-ASK1-CT, pcDNA3-Flag-ASK1WT, pcDNA3-Flag-Trx, pRK-Flag-TRAF2, and pCR3-Flag-TRAF6 have been described previously (12, 15, 17, 21). A Flag tag was inserted at the N terminus of Trx-CS in pcDNA3, which has been described previously (17). Flag-ASK1
N and Flag-ASK1
C were constructed in pcDNA3, using cDNAs from their respective HA-tagged vectors. cDNAs encoding ASK1-NT277, ASK1-NT384, ASK1-NT(277-655), ASK1-NT(384-655), ASK1
47-120, ASK1
244-277, ASK1
277, ASK1
384, and ASK1
NCC were generated by PCR, using mouse ASK1 cDNA as a template, and inserted into pcDNA3 with an HA or Flag tag. cDNAs encoding N-terminal fragments of ASK1 (1-277, 1-244, and 46-277) and Trx (Trx and Trx-CS) were subcloned into pEG202 and pJG4-5, respectively, for yeast two-hybrid analysis.
Yeast two-hybrid system. The reporter plasmid pJK103, encoding ß-galactosidase, and a prey plasmid encoding Trx or Trx-CS fused to the transcriptional activation domain were cotransformed into Saccharomyces cerevisiae EGY188 with bait plasmids encoding the N-terminal (NT) fragments corresponding to amino acids (aa) 1 to 277, 1 to 244, and 46 to 277 of ASK1 fused to the DNA-binding domain. Each transformant was patched onto a 5-bromo-4-chloro-3-indolyl-ß-D-galactopyranoside (X-Gal; Calbiochem)-containing galactose-positive and His– Trp– Ura– plate (SG-HWU/X-Gal).
Immunoblotting analysis. Cells were lysed in lysis buffer A, containing 150 mM NaCl, 20 mM Tris-HCl, pH 7.5, 10 mM EDTA, 1% Triton X-100, 1% deoxycholate, 1 mM phenylmethylsulfonyl fluoride, and 1.5% aprotinin, or lysis buffer B, containing 150 mM NaCl, 50 mM Tris-HCl, pH 8.0, 1% Nonidet P-40, 0.5% deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 1 mM phenylmethylsulfonyl fluoride, and 1.5% aprotinin. Cell extracts were clarified by centrifugation, and the supernatants were resolved by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene difluoride membranes. After being blocked with 5% skim milk in TBS-T (150 mM NaCl, 50 mM Tris-HCl, pH 8.0, and 0.05% Tween 20) for 3 h, the membranes were probed with antibodies. The antibody-antigen complexes were detected using an enhanced chemiluminescence system (Amersham Biosciences).
Coimmunoprecipitation assay. Cells were lysed in lysis buffer A. Cell extracts were clarified by centrifugation, and the supernatants were immunoprecipitated with anti-Flag M2 affinity gel or anti-HA, anti-Trx, or anti-immunoglobulin G1 (anti-IgG1) antibody, using protein G-Sepharose (Amersham Biosciences). The beads were washed twice with a washing buffer containing 1% Triton X-100, 500 mM NaCl, 20 mM Tris-HCl, pH 7.5, 5 mM EGTA, and 2 mM dithiothreitol, followed by two washes with a washing buffer containing 150 mM NaCl, 20 mM Tris-HCl, pH 7.5, and 5 mM EGTA. The beads were subjected to SDS-PAGE followed by immunoblotting analysis.
Measurement of caspase-3 activity.
HEK293A cells were transiently transfected with vector alone, Flag-ASK1WT, Flag-ASK1
277, or Flag-ASK1
384. After 48 h, cells were washed with phosphate-buffered saline and lysed in lysis buffer B. Caspase-3-like activity was measured with a CPP32/caspase-3 fluorometric protease assay kit (MBL) following the manufacturer's instructions, in which a fluorogenic synthetic peptide, DEVD-7-amino-4-trifluoromethyl coumarine (AFC), was used as a substrate. The fluorescence of the released AFC was measured at an excitation wavelength of 380 nm and an emission wavelength of 510 nm. To confirm the appropriate expression of transfected plasmids, the same lysates in duplicate wells were combined and verified by immunoblot analysis.
RNA interference.
Small interfering RNAs (siRNAs) for human TRAF2 and TRAF6 were purchased from Invitrogen (Stealth Select RNAi RNAs HSS110961 and HSS110969, respectively). A Stealth RNA interference negative control (Invitrogen) was used as a control. HEK293A cells were transfected with siRNAs by using Lipofectamine 2000 (Invitrogen). After 24 h, cells were transfected with the indicated combinations of Flag-ASK1
C and HA-ASK1
C. After another 24 h, cells were treated with 5.0 mM H2O2 for 20 min. Cell lysates were immunoprecipitated with anti-Flag antibody. Immunoprecipitates and aliquots of each lysate were subjected to SDS-PAGE followed by immunoblotting with the antibodies indicated in Fig. 6C.
|
| RESULTS |
|---|
|
|
|---|
277, which lacked the N-terminal 277 aa, did not associate with Trx. ASK1
47-120 and ASK1
244-277, which lacked the N- and C-terminal portions of the Trx-binding region of ASK1 (aa 46 to 277 in ASK1), respectively, also failed to associate with Trx. We also examined the interaction between the HA-tagged aa 46-to-277 region of ASK1 and endogenous Trx in HEK293A cells. However, we failed to detect the interaction because of the nonspecific background (see Fig. S1A in the supplemental material). We then transfected the Flag-tagged aa 46-to-277 region of ASK1 (Flag-ASK1-NT46-277) into HEK293A cells. Cell lysates were subjected to immunoprecipitation with anti-Flag antibody, and coimmunoprecipitated endogenous Trx was detected by immunoblotting with anti-Trx antibody (see Fig. S1B in the supplemental material). This observation clearly demonstrates that endogenous Trx interacts with ASK1-NT46-277. Taken together, these results suggest that aa 46 to 277 of ASK1 are necessary and sufficient for association with Trx.
|
Identification of the TRAF-binding region of ASK1.
TRAF2 and TRAF6 have been found to be required for ROS-induced activation of ASK1 (16). To elucidate the mechanism of activation of ASK1 by TRAF2 and TRAF6, we next determined the TRAF2- and TRAF6-binding regions within ASK1. When various HA-tagged deletion mutants of ASK1 were cotransfected with Flag-TRAF2 or Flag-TRAF6 into HEK293A cells, both the N-terminal (ASK1
C and ASK1-NT) and C-terminal (ASK1
N and ASK1-CT) domains, but not a catalytic domain (ASK1-KD), of ASK1 were found to be associated with TRAF2 (Fig. 2A and B). These findings are consistent with those of a previous study, which showed that TRAF2 interacted with both the ASK1 N-terminal (aa 1 to 460) and C-terminal (aa 937 to 1375) noncatalytic regions (9). High levels of ASK1-NT were associated with TRAF2, even though ASK1-NT was expressed only at low levels (Fig. 2B). This implies a much stronger interaction between TRAF2 and ASK1-NT than that with the other truncated ASK1 mutants, suggesting that TRAF2 preferentially associates with ASK1 at the N-terminal region. Similar to TRAF2, TRAF6 interacted with both the N- and C-terminal regions of ASK1 (Fig. 2C). Furthermore, TRAF6 also interacted strongly with ASK1 at the N-terminal region. Note that in the upper panels of Fig. 2B and C, HA-ASK1 in some lanes without TRAF2 or TRAF6 expression represents nonspecifically coprecipitated HA-ASK1 obtained with the beads. Nevertheless, TRAF-dependent interactions with ASK1 at the N-terminal region were clearly detected, suggesting that both TRAF2 and TRAF6 preferentially interact with ASK1 at the N-terminal region.
|
Trx-binding-region truncated mutants of ASK1 strongly interact with TRAF2 and TRAF6.
In resting cells, Trx directly binds to and inhibits the kinase activity of ASK1. In previous studies, we found that ROS-dependent dissociation of Trx and reciprocal recruitment of TRAF2 and TRAF6 to ASK1 are required for the activation of ASK1 (16). In addition, it has been shown that overexpression of Trx inhibits ASK1-TRAF2 interaction and that overexpression of TRAF2 inhibits Trx-ASK1 interaction (9). These previous findings suggest the possibility that the regions of Trx and TRAFs that bind ASK1 overlap in the primary structure of ASK1. However, coimmunoprecipitation analysis (Fig. 1 and 2) revealed that the regions that bind ASK1 are close but not overlapping in the primary structure of ASK1, suggesting that Trx and TRAFs bind competitively to ASK1 when ASK1 forms its tertiary structure. We then employed Trx-binding-region truncated mutants of ASK1, namely, ASK1
277 (aa 278 to 1380) and ASK1
384 (aa 385 to 1380), to examine the interaction between ASK1 and TRAFs in the absence of effects of Trx (Fig. 3A). When HA-tagged ASK1 and its mutants were cotransfected with Flag-TRAF2 or Flag-TRAF6 in HEK293A cells, coimmunoprecipitation analysis showed that both ASK1
277 and ASK1
384 associated with TRAF2 and TRAF6 much more strongly than did the WT (Fig. 3B and C). ASK1
277 and ASK1
384 were confirmed not to interact with endogenous Trx in HEK293A cells (Fig. 3D). These results further support the previous finding that the binding of Trx to ASK1 interferes with access of TRAF2 to ASK1 (9).
|
277 and ASK1
384 did not interact with Trx but strongly interacted with TRAF2 and TRAF6 prompted us to examine their kinase activities. We first examined the effect of Trx binding on basal activity of ASK1 by immunoblotting analysis using phospho-ASK1 antibody. The basal activity of WT ASK1 (ASK1WT) but not that of ASK1
277 was strongly inhibited by coexpression of Trx (Fig. 4A), confirming that Trx suppresses ASK1 activity by direct binding to the N terminus of ASK1. We next compared the kinase activities of ASK1WT, ASK1
277, and ASK1
384 (Fig. 4B). ASK1
277, which contains the NCC domain but not the Trx-binding domain, exhibited higher basal activity than did ASK1WT and induced the activation of endogenous JNK (Fig. 4B). In contrast, the kinase activity of ASK1
384, which lacks not only the Trx-binding region but also the NCC domain, was lower than that of ASK1
277, whereas both of the mutants interacted strongly with TRAF2 and TRAF6 (Fig. 4B). These findings suggested that binding of TRAF2 or TRAF6 to ASK1 is not sufficient for activation and that the NCC domain of ASK1 is also required for full activation of ASK1. In order to determine whether the NCC domain is required for ASK1 activity, we generated an ASK1 mutant that lacks the NCC domain, namely, ASK1
NCC (Fig. 4C). When HEK293A cells transfected with HA-ASK1WT or HA-ASK1
NCC were stimulated with H2O2, ASK1
NCC exhibited much lower activity than did ASK1WT (Fig. 4D). These findings suggested that not only TRAF2 or TRAF6 binding to ASK1 but also certain function of the NCC domain of ASK1 is required for ROS-induced activation of ASK1.
|
277 was much lower than that of ASK1WT, ASK1
277 induced caspase-3-like activity more strongly than did ASK1WT. On the other hand, ASK1
384 induced caspase-3-like activity to a moderate extent, in good correlation with its relative kinase activity, as shown in Fig. 4B. These findings suggest that the NCC domain is required for full activation of ASK1, which contributes to effective transmission of proapoptotic signals.
We have previously shown that ASK1
N (aa 656 to 1380), which lacks the entire N-terminal region, acts as a constitutively active mutant (17). We therefore compared the kinase activity of ASK1
N with those of ASK1
277 and ASK1
384. Unexpectedly, ASK1
N exhibited almost the same activity as ASK1
384, although ASK1
N does not possess a TRAF-binding region (aa 384 to 655) (Fig. 4F). ASK1
N and ASK1
384 may mimic an intermediately active form that is liberated from inhibition by Trx but not fully activated due to lack of the NCC domain.
Homophilic interaction of ASK1 through the NCC domain.
We previously demonstrated that the CCC domain is required for homo-oligomerization of ASK1, which prompted us to examine whether the NCC domain is also required for homophilic interaction of ASK1. We generated the ASK1 fragments ASK1-NT384 and ASK1-NT277 (Fig. 5A). When Flag-tagged ASK1-NT384 (Flag-ASK1-NT384), which contains the NCC domain in addition to the Trx-binding domain, was cotransfected with HA-ASK1-NT384 into HEK293A cells, the interaction of Flag-ASK1-NT384 with HA-ASK1-NT384 was much stronger than that of Flag-ASK1-NT277 with HA-ASK1-NT277 (Fig. 5B). These findings suggested that the NCC domain contributes to homophilic interaction of ASK1. The existence of such a contribution was supported by the finding that homophilic interaction of ASK1
C, which lacks the C-terminal region, including the CCC domain (Fig. 5A), was also detected (Fig. 5C, lane 6). Homophilic interaction of ASK1WT was much stronger than that of ASK1
C or ASK1-NT384 (Fig. 5C), indicating that ASK1 proteins associate with each other mainly through the C-terminal region, as previously reported (21). Importantly, however, these findings also suggest that the NCC domain serves as an additional interface for the CCC domain-mediated preformed ASK1 complex.
|
To evaluate the effect of Trx on the ROS-dependent weak interaction through the NCC domain, we next designed a similar experiment, as shown in Fig. 6A, but using ASK1
C instead of full-length ASK1. We found that the association of Flag-ASK1
C with HA-ASK1
C was readily inhibited by coexpression of Flag-Trx (Fig. 6B, top panel), suggesting that Trx inhibits NCC domain- but not CCC domain-dependent homophilic interaction of ASK1. Endogenous Trx may interrupt the homophilic interaction of exogenously expressed ASK1
C to some extent. If this is the case, inactivation of endogenous Trx should enhance the homophilic interaction of ASK1
C. To test this hypothesis, we examined the effect of H2O2 on the homophilic interaction of ASK1
C. Cell lysates from H2O2-treated and untreated HEK293A cells coexpressing Flag- and HA-ASK1
C were subjected to coimmunoprecipitation analysis. The association of Flag-ASK1
C with HA-ASK1
C was augmented by treatment with H2O2 (Fig. 6C, control lanes), although this augmentation was undetectable in the case of ASK1WT (21). Furthermore, endogenous Trx dissociated from ASK1
C upon treatment with H2O2 (Fig. 6D). These findings suggested that the NCC domain-mediated homophilic interaction of ASK1, which is suppressed by association with Trx under nonstress conditions, is induced by ROS-dependent dissociation of Trx from ASK1.
Since the TRAF-binding region is adjacent to the NCC domain as well as the Trx-binding region, we next examined whether TRAF2 and TRAF6 affect the homophilic interaction of ASK1
C. In contrast to Trx, we found that association of Flag-ASK1
C with HA-ASK1
C was promoted by coexpression of Flag-TRAF2 or Flag-TRAF6 (Fig. 6E and F, top panels), suggesting that TRAF2 and TRAF6 activate ASK1 by promoting N-terminal homophilic interaction of ASK1. Furthermore, the H2O2-induced homophilic interaction of ASK1
C was inhibited by double knockdown of TRAF2 and TRAF6 (Fig. 6C, right half), suggesting that TRAF2 and TRAF6 are required for ROS-induced homophilic interaction of ASK1 through the NCC domain.
| DISCUSSION |
|---|
|
|
|---|
277 and ASK1
384, strongly interact with TRAF2 and TRAF6; (iv) the ASK1
277 mutant, which lacks the Trx-binding region, is a constitutively active form and strongly induces the activation of JNK and caspase-3, while ASK1
384, which lacks not only the Trx-binding region but also the NCC domain (aa 297 to 324), has reduced activity compared with ASK1
277; (v) homophilic interaction of the N terminus of ASK1 is mediated by the NCC domain of ASK1, adjacent to the Trx-binding region and the TRAF-binding region; (vi) the NCC domain is required for ROS-induced activation of ASK1; and (vii) Trx inhibits NCC-dependent homophilic interaction of ASK1, which is promoted by overexpression of TRAFs or oxidative stress. Based on these observations, we present a schematic model of the mechanisms of regulation of ASK1 activation by Trx and TRAFs (Fig. 7). In nonstressed cells, the reduced form of Trx binds to the Trx-binding region of ASK1 and inhibits NCC domain- but not CCC domain-mediated homophilic interaction, possibly through mechanisms involving steric hindrance. Upon ROS stimulation, Trx is readily oxidized and ASK1 thus unbinds from oxidized Trx, enabling ASK1 to interact with TRAF2 and TRAF6. ASK1 is thus activated by trans-autophosphorylation, which is dependent on TRAF-mediated homophilic interaction through the N-terminal region of ASK1.
|
277 mutant, which lacks the Trx-binding region, is a constitutively and fully activated form that strongly induces cell death. We have previously shown that the N-terminal region of ASK1 is important for Trx-mediated regulation of ASK1 kinase activity and that ASK1
N (aa 656 to 1380), which lacks the entire N-terminal region, acts as an active mutant (17). In fact, the kinase activity of ASK1
N is stronger than that of ASK1WT (data not shown) but weaker than that of ASK1
277 (Fig. 4F). ASK1
N lacks not only the Trx-binding region but also the NCC domain and the TRAF-binding region. It may thus be a partially active form that is liberated from inhibition by Trx but not fully activated due to a lack of recruitment of TRAF2 and TRAF6, whereas ASK1
277 mimics a fully activated form of ASK1. Unexpectedly, however, ASK1
277 exhibited slight activation in response to ROS, although the increases of activated ASK1
277 were lower than those of activated ASK1WT (see Fig. S2 in the supplemental material). It is conceivable that endogenous ASK1 that formed a complex with ASK1
277 was activated by ROS and thereby also activated ASK1
277. On the other hand, these results may also suggest that there are unidentified ROS-dependent modifications of ASK1, TRAF2, or TRAF6. We found that the Trx-binding region is adjacent to the NCC domain, which is required for homophilic interaction and ROS-induced activation of ASK1. The presence of an inhibitory domain adjacent to the activation domain may favor rapid and precise regulation. It has been reported that many other negative regulators of ASK1 directly bind to or modify the N-terminal region of ASK1. Raf-1 interacts with the N-terminal region of ASK1 and inhibits ASK1 activity in a fashion independent of Raf-1 kinase activity (1). Akt directly phosphorylates Ser83 in the human ASK1 N-terminal region and down-regulates ASK1 activity (8). The type 1 insulin-like growth factor receptor suppresses ASK1 activity by phosphorylation of multiple Tyr residues in the N-terminal region of ASK1 (3). The N-terminal region of ASK1 is a common target site for these negative regulators of ASK1 as well as for Trx. These molecules might thus inhibit ASK1 activity through interference with NCC domain homophilic interaction.
We have recently shown that endogenous ASK1 constitutively forms the so-called ASK1 signalosome as a homo- oligomerized but still inactive high-molecular-mass complex including Trx (16), indicating that homo-oligomerization of ASK1 through the CCC domain is required but not sufficient for ASK1 activation. Consistent with this, the present study clearly showed that not only CCC domain-mediated homo-oligomerization but also ROS-induced NCC domain interaction is required for full activation of ASK1. Furthermore, upon ROS stimulation, the ASK1 signalosome unbinds from oxidized Trx and forms a fully activated higher-molecular-mass complex, in part by recruitment of TRAF2 and TRAF6 (16). However, the precise mechanisms by which TRAF2 and TRAF6 function as activators of ASK1 have remained poorly understood (9, 15). In this study, we also identified the TRAF-binding region adjacent to the NCC domain, which may effectively promote the N-terminal homophilic interaction of ASK1, resulting in full activation of ASK1. Given our previous observation that a TRAF2 mutant lacking a ring finger domain can no longer activate ASK1 (15), it is conceivable that the ring finger domains of TRAF2 and TRAF6 are required to accelerate N-terminal homophilic interaction of ASK1 and are thus necessary for activation of ASK1. Interestingly, the ring finger domain is required for the E3 ubiquitin ligase activity of TRAF2 and TRAF6. ROS-dependent ubiquitination of TRAF2 and TRAF6 themselves or of ASK1 might thus be involved in ROS-induced mechanisms of activation of ASK1.
Exposure of aerobic organisms to oxidative stress is continuous and unavoidable. ROS generation and redox imbalance are closely linked to a wide range of diseases and conditions, such as inflammation, ischemia-reperfusion injury, cancer, neurodegenerative disorders, and aging. It has been reported that ROS-mediated ASK1 activation is involved in a variety of disorders, such as inflammation, neurodegeneration, and cardiac hypertrophy and remodeling (13). Further studies on the mechanisms of regulation of ASK1 and the development of ASK1-targeting drugs may contribute to the treatment of various diseases caused by oxidative stress.
| ACKNOWLEDGMENTS |
|---|
This work was supported by grants-in-aid for scientific research from the Ministry of Education, Sciences, and Culture of Japan, by CREST, the Japan Science and Technology Corporation, and by the Center of Excellence (COE) program.
| FOOTNOTES |
|---|
Published ahead of print on 27 August 2007. ![]()
Supplemental material for this article may be found at http://mcb.asm.org/. ![]()
| REFERENCES |
|---|
|
|
|---|
2. Fujino, G., T. Noguchi, K. Takeda, and H. Ichijo. 2006. Thioredoxin and protein kinases in redox signaling. Semin. Cancer Biol. 16:427-435.[CrossRef][Medline]
3. Galvan, V., A. Logvinova, S. Sperandio, H. Ichijo, and D. E. Bredesen. 2003. Type 1 insulin-like growth factor receptor (IGF-IR) signaling inhibits apoptosis signal-regulating kinase 1 (ASK1). J. Biol. Chem. 278:13325-13332.
4. Hashimoto, Y., T. Niikura, T. Chiba, E. Tsukamoto, H. Kadowaki, H. Nishitoh, Y. Yamagishi, M. Ishizaka, M. Yamada, M. Nawa, K. Terashita, S. Aiso, H. Ichijo, and I. Nishimoto. 2003. The cytoplasmic domain of Alzheimer's amyloid-beta protein precursor causes sustained apoptosis signal-regulating kinase 1/c-Jun NH2-terminal kinase-mediated neurotoxic signal via dimerization. J. Pharmacol. Exp. Ther. 306:889-902.
5. Hatai, T., A. Matsuzawa, S. Inoshita, Y. Mochida, T. Kuroda, K. Sakamaki, K. Kuida, S. Yonehara, H. Ichijo, and K. Takeda. 2000. Execution of apoptosis signal-regulating kinase 1 (ASK1)-induced apoptosis by the mitochondria-dependent caspase activation. J. Biol. Chem. 275:26576-26581.
6. Ichijo, H., E. Nishida, K. Irie, P. ten Dijke, M. Saitoh, T. Moriguchi, M. Takagi, K. Matsumoto, K. Miyazono, and Y. Gotoh. 1997. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 275:90-94.
7. Kadowaki, H., H. Nishitoh, F. Urano, C. Sadamitsu, A. Matsuzawa, K. Takeda, H. Masutani, J. Yodoi, Y. Urano, T. Nagano, and H. Ichijo. 2005. Amyloid beta induces neuronal cell death through ROS-mediated ASK1 activation. Cell Death Differ. 12:19-24.[CrossRef][Medline]
8. Kim, A. H., G. Khursigara, X. Sun, T. F. Franke, and M. V. Chao. 2001. Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. Mol. Cell. Biol. 21:893-901.
9. Liu, H., H. Nishitoh, H. Ichijo, and J. M. Kyriakis. 2000. Activation of apoptosis signal-regulating kinase 1 (ASK1) by tumor necrosis factor receptor-associated factor 2 requires prior dissociation of the ASK1 inhibitor thioredoxin. Mol. Cell. Biol. 20:2198-2208.
10. Liu, Y., and W. Min. 2002. Thioredoxin promotes ASK1 ubiquitination and degradation to inhibit ASK1-mediated apoptosis in a redox activity-independent manner. Circ. Res. 90:1259-1266.
11. Matsuzawa, A., K. Saegusa, T. Noguchi, C. Sadamitsu, H. Nishitoh, S. Nagai, S. Koyasu, K. Matsumoto, K. Takeda, and H. Ichijo. 2005. ROS-dependent activation of the TRAF6-ASK1-p38 pathway is selectively required for TLR4-mediated innate immunity. Nat. Immunol. 6:587-592.[CrossRef][Medline]
12. Morita, K., M. Saitoh, K. Tobiume, H. Matsuura, S. Enomoto, H. Nishitoh, and H. Ichijo. 2001. Negative feedback regulation of ASK1 by protein phosphatase 5 (PP5) in response to oxidative stress. EMBO J. 20:6028-6036.[CrossRef][Medline]
13. Nagai, H., T. Noguchi, K. Takeda, and H. Ichijo. 2007. Pathophysiological roles of ASK1-MAP kinase signaling pathways. J. Biochem. Mol. Biol. 40:1-6.[Medline]
14. Nishitoh, H., A. Matsuzawa, K. Tobiume, K. Saegusa, K. Takeda, K. Inoue, S. Hori, A. Kakizuka, and H. Ichijo. 2002. ASK1 is essential for endoplasmic reticulum stress-induced neuronal cell death triggered by expanded polyglutamine repeats. Genes Dev. 16:1345-1355.
15. Nishitoh, H., M. Saitoh, Y. Mochida, K. Takeda, H. Nakano, M. Rothe, K. Miyazono, and H. Ichijo. 1998. ASK1 is essential for JNK/SAPK activation by TRAF2. Mol. Cell 2:389-395.[CrossRef][Medline]
16. Noguchi, T., K. Takeda, A. Matsuzawa, K. Saegusa, H. Nakano, J. Gohda, J. Inoue, and H. Ichijo. 2005. Recruitment of tumor necrosis factor receptor-associated factor family proteins to apoptosis signal-regulating kinase 1 signalosome is essential for oxidative stress-induced cell death. J. Biol. Chem. 280:37033-37040.
17. Saitoh, M., H. Nishitoh, M. Fujii, K. Takeda, K. Tobiume, Y. Sawada, M. Kawabata, K. Miyazono, and H. Ichijo. 1998. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J. 17:2596-2606.[CrossRef][Medline]
18. Takeda, K., T. Hatai, T. S. Hamazaki, H. Nishitoh, M. Saitoh, and H. Ichijo. 2000. Apoptosis signal-regulating kinase 1 (ASK1) induces neuronal differentiation and survival of PC12 cells. J. Biol. Chem. 275:9805-9813.
19. Takeda, K., A. Matsuzawa, H. Nishitoh, K. Tobiume, S. Kishida, J. Ninomiya-Tsuji, K. Matsumoto, and H. Ichijo. 2004. Involvement of ASK1 in Ca2+-induced p38 MAP kinase activation. EMBO Rep. 5:161-166.[CrossRef][Medline]
20. Tobiume, K., A. Matsuzawa, T. Takahashi, H. Nishitoh, K. Morita, K. Takeda, O. Minowa, K. Miyazono, T. Noda, and H. Ichijo. 2001. ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis. EMBO Rep. 2:222-228.[CrossRef][Medline]
21. Tobiume, K., M. Saitoh, and H. Ichijo. 2002. Activation of apoptosis signal-regulating kinase 1 by the stress-induced activating phosphorylation of preformed oligomer. J. Cell Physiol. 191:95-104.[CrossRef][Medline]
22. Zhang, R., R. Al-Lamki, L. Bai, J. W. Streb, J. M. Miano, J. Bradley, and W. Min. 2004. Thioredoxin-2 inhibits mitochondria-located ASK1-mediated apoptosis in a JNK-independent manner. Circ. Res. 94:1483-1491.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|